Aramchol
- Generic Name
- Aramchol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C44H79NO5
- CAS Number
- 246529-22-6
- Unique Ingredient Identifier
- QE1Q24M65Y
- Background
Aramchol has been used in trials studying the treatment of HIV, Gallstones, Fatty Liver, Metabolic Syndrome, and Nonalcoholic Steatohepatitis, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Liver Fibrosis Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Epidemiology, Medication, and Companies
The Liver Fibrosis market, valued at ~USD 2,308 million in 2023, is expected to grow significantly by 2034, driven by rising prevalence and new therapies. The US leads in market size and cases, with Germany leading in the EU. Key companies include Gilead Sciences, Pfizer, and AstraZeneca, focusing on emerging treatments like Efruxifermin and Aramchol.
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
Aramchol 300mg BID shows significant anti-fibrotic effects in MASH patients, confirmed by NASH CRN, paired ranked reading, and AI digital analysis. Published in Hepatology, the study highlights Aramchol's potential as a therapeutic option for MASH and fibrosis.
Galmed Announces an Expansion of its Activities to Cancer and Major Cardiometabolic Diseases
Galmed Pharmaceuticals plans to expand drug development activities, focusing on novel Aramchol-based combinations for advanced colorectal and hepatic cancers, and cardiac fibrosis. The expansion is driven by recent scientific publications highlighting SCD1 inhibition's potential in cardiometabolic diseases, cancer, and neuroprotection.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath